AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition.

EU approves AstraZeneca’s Calquence in combo with venetoclax, with or without obinutuzumab to treat adult patients with previously untreated CLL: Cambridge, UK Saturday, June 7, ...

The pharmaceutical company AstraZeneca has filed a federal lawsuit against Utah Attorney General Derek Brown and Utah ...

University of Cambridge-led trial shows significant improvement in outcomes for inherited, aggressive forms of breast cancerA ...

The prestigious 2025 Prix Galien UK Lifetime Achievement Award was bestowed upon Dame June Raine, Former Chief Executive ...

Multinationals on China: China has set a GDP growth target of around 5% for 2025. How do you view this target and China’s ...

Adding an SGLT2 inhibitor to finerenone in CKD and type 2 diabetes yields “remarkable” albuminuria reductions that may, if ...

Sortera Bio, a Cambridge biotech based on IP developed at the MRC Laboratory of Molecular Biology, has attracted big hitting ...

Collaboration leverages cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and seeks to capture commercial potential in the $15 billion animal ...

The Cambridge Independent Business Awards 2025 are now open for entry. Following the success of our inaugural awards last year, we are delighted to announce that the search is now on for the best in ...

Even years later, patients whose symptoms were initially dismissed experience distrust and uncertainty with clinicians.